#AVBP↓

AVBP/ 12/23/2025 · 5:56 AM

Cantor Fitzgerald Starts Coverage on ArriVent Biopharma with Strong Upside

Cantor Fitzgerald initiates coverage on ArriVent Biopharma with an Overweight rating, highlighting strong Phase 3 potential and significant upside.